Italian authorities released the director of a notorious detention camp who had been arrested in Turin on an ICC war crimes warrant. Italian police were acting on an arrest warrant from the ...

Verdiva launched with $411 million. Indian drugmaker Anthem Biosciences filed for an IPO worth $397 million. Tenvie Therapeutics emerged with $200 million. Maze Therapeutics files for $115 million ...

Tenvie Therapeutics Inc. is getting a set of small-molecule drugs — specifically, ones aimed at tamping down inflammation, rescuing metabolic dysfunction and restoring lysosomal function ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results The Arch-backed startup begins life with several assets acquired from Denali Therapeutics.

The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.

ARCH Venture Partners, F-Prime Capital, and Mubadala Capital lead $200 million investment to fuel acceleration of Tenvie into a multi-clinical asset company SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 ...

A new start­up has emerged with $200 mil­lion and ac­cess to mul­ti­ple pre­clin­i­cal drug can­di­dates from neu­ro­science drug­mak­er De­nali Ther­a­peu­tics.